IL122216A - Dolastatin derivatives against cancer and their preparation - Google Patents

Dolastatin derivatives against cancer and their preparation

Info

Publication number
IL122216A
IL122216A IL12221696A IL12221696A IL122216A IL 122216 A IL122216 A IL 122216A IL 12221696 A IL12221696 A IL 12221696A IL 12221696 A IL12221696 A IL 12221696A IL 122216 A IL122216 A IL 122216A
Authority
IL
Israel
Prior art keywords
residue
methylprolyl
tert
xaa val
pro
Prior art date
Application number
IL12221696A
Other languages
English (en)
Hebrew (he)
Other versions
IL122216A0 (en
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL122216A0 publication Critical patent/IL122216A0/xx
Publication of IL122216A publication Critical patent/IL122216A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IL12221696A 1995-06-07 1996-06-03 Dolastatin derivatives against cancer and their preparation IL122216A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002393 WO1996040752A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (2)

Publication Number Publication Date
IL122216A0 IL122216A0 (en) 1998-04-05
IL122216A true IL122216A (en) 2002-02-10

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12221596A IL122215A (en) 1995-06-07 1996-06-03 Dolastatin derivatives as antineoplastics and their preparation
IL12221696A IL122216A (en) 1995-06-07 1996-06-03 Dolastatin derivatives against cancer and their preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL12221596A IL122215A (en) 1995-06-07 1996-06-03 Dolastatin derivatives as antineoplastics and their preparation

Country Status (33)

Country Link
US (1) US5831002A (de)
EP (2) EP0871656B1 (de)
JP (2) JP4221062B2 (de)
KR (2) KR100437986B1 (de)
CN (2) CN1182154C (de)
AR (2) AR003136A1 (de)
AT (2) ATE224910T1 (de)
AU (2) AU725170B2 (de)
BG (2) BG102125A (de)
BR (2) BR9609424A (de)
CA (2) CA2219819C (de)
CO (2) CO4700527A1 (de)
CZ (2) CZ293683B6 (de)
DE (2) DE69623472T2 (de)
DK (2) DK0871656T3 (de)
ES (2) ES2188759T3 (de)
HR (2) HRP960257A2 (de)
HU (2) HU228071B1 (de)
IL (2) IL122215A (de)
MX (2) MX9709147A (de)
MY (2) MY119042A (de)
NO (2) NO317670B1 (de)
NZ (2) NZ310444A (de)
PL (2) PL185762B1 (de)
PT (2) PT871656E (de)
RO (2) RO118953B1 (de)
SI (2) SI0832104T1 (de)
SK (1) SK282466B6 (de)
TR (2) TR199701545T1 (de)
TW (2) TW508357B (de)
UA (2) UA46776C2 (de)
WO (2) WO1996040751A1 (de)
ZA (2) ZA964710B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
EP2266607A3 (de) 1999-10-01 2011-04-20 Immunogen, Inc. Immunokonjugate für Krebsbehandlung
WO2002088298A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
WO2003051835A2 (en) * 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (de) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Konjugate aus ligand, linker und zytotoxischem agens sowie verwandte zusammensetzungen und verwendungsverfahren
US8568637B2 (en) 2004-08-02 2013-10-29 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
EP2049524A2 (de) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap-hemmer
NZ580271A (en) * 2007-04-12 2011-03-31 Scinopharm Taiwan Ltd Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
AU2011352145A1 (en) 2010-12-30 2013-07-18 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP6581774B2 (ja) * 2011-05-27 2019-09-25 アンブルックス, インコーポレイテッドAmbrx, Inc. 非天然アミノ酸結合ドラスタチン誘導体を含有する化合物またはその化合物の溶媒和物、およびドラスタチンアナログを誘導体化するための方法
EP3089757A1 (de) 2014-01-03 2016-11-09 AbbVie Inc. Feste antivirale darreichungsformen
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
UA45304C2 (uk) * 1992-05-20 2002-04-15 Басф Аг Похідні пептиду або їх солі, фармацевтична композиція
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides

Also Published As

Publication number Publication date
DE69623472T2 (de) 2003-08-21
NZ310444A (en) 1999-11-29
HRP960257A2 (en) 1998-02-28
AU6124296A (en) 1996-12-30
IL122215A0 (en) 1998-04-05
CA2219818C (en) 2008-05-20
SK282466B6 (sk) 2002-02-05
US5831002A (en) 1998-11-03
ZA964710B (en) 1997-12-08
PL323726A1 (en) 1998-04-14
NO975711L (no) 1998-01-30
AR003136A1 (es) 1998-07-08
CZ293682B6 (cs) 2004-07-14
NO975711D0 (no) 1997-12-05
EP0871656B1 (de) 2002-09-25
ZA964711B (en) 1997-12-08
AU725170B2 (en) 2000-10-05
ATE224910T1 (de) 2002-10-15
CN1182154C (zh) 2004-12-29
CA2219819A1 (en) 1996-12-19
EP0871656A1 (de) 1998-10-21
CA2219819C (en) 2008-05-20
CN1187199A (zh) 1998-07-08
DK0871656T3 (da) 2003-01-27
CA2219818A1 (en) 1996-12-19
PL185763B1 (pl) 2003-07-31
RO119783B1 (ro) 2005-03-30
JPH11504652A (ja) 1999-04-27
WO1996040752A1 (en) 1996-12-19
MY124487A (en) 2006-06-30
CZ376597A3 (cs) 1998-06-17
TW424096B (en) 2001-03-01
EP0832104B1 (de) 2002-09-04
DE69623992T2 (de) 2003-05-22
CZ376397A3 (cs) 1998-06-17
KR19990022583A (ko) 1999-03-25
AR003427A1 (es) 1998-08-05
JPH11504653A (ja) 1999-04-27
EP0832104A1 (de) 1998-04-01
TW508357B (en) 2002-11-01
KR19990022582A (ko) 1999-03-25
AU6124196A (en) 1996-12-30
UA46775C2 (uk) 2002-06-17
CZ293683B6 (cs) 2004-07-14
HUP9801817A2 (hu) 1998-11-30
NO317670B1 (no) 2004-11-29
NO975710L (no) 1998-02-02
RO118953B1 (ro) 2004-01-30
PL185762B1 (pl) 2003-07-31
MX9709146A (es) 1998-03-31
ATE223431T1 (de) 2002-09-15
UA46776C2 (uk) 2002-06-17
HRP960277A2 (en) 1997-10-31
AU725164B2 (en) 2000-10-05
ES2188759T3 (es) 2003-07-01
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
BR9609424A (pt) 2000-03-28
PT871656E (pt) 2002-12-31
JP4221062B2 (ja) 2009-02-12
HUP9801910A2 (hu) 1999-01-28
MY119042A (en) 2005-03-31
SI0832104T1 (en) 2003-08-31
MX9709147A (es) 1998-03-31
WO1996040751A1 (en) 1996-12-19
SI0871656T1 (en) 2003-08-31
NO318384B1 (no) 2005-03-14
HUP9801817A3 (en) 1999-06-28
ES2186783T3 (es) 2003-05-16
DE69623472D1 (de) 2002-10-10
SK165397A3 (en) 1998-10-07
HUP9801910A3 (en) 1999-06-28
DE69623992D1 (de) 2002-10-31
HU228073B1 (hu) 2012-09-28
PL323723A1 (en) 1998-04-14
HU228071B1 (hu) 2012-09-28
BG102125A (en) 1998-09-30
BR9609423A (pt) 1999-06-29
CN1182153C (zh) 2004-12-29
TR199701544T1 (xx) 1998-03-21
JP3957751B2 (ja) 2007-08-15
TR199701545T1 (xx) 1998-04-21
CO4700526A1 (es) 1998-12-29
IL122216A0 (en) 1998-04-05
NO975710D0 (no) 1997-12-05
KR100437986B1 (ko) 2004-09-18
CO4700527A1 (es) 1998-12-29
KR100437985B1 (ko) 2004-09-18
IL122215A (en) 2001-08-26
BG102152A (en) 1998-09-30
NZ310443A (en) 1999-10-28
PT832104E (pt) 2002-12-31

Similar Documents

Publication Publication Date Title
CA2219819C (en) Novel compounds, the preparation and use thereof
AU679479B2 (en) Dolostatin analog
EP0642530B1 (de) Derivate des Dolastatin
IL166853A (en) Antineoplastic peptides, their preparation and various uses thereof
AU775090B2 (en) Antineoplastic peptides
SK165497A3 (en) Peptides, preparation method thereof and pharmaceutical composition containing the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired